Recently, the list of Guangzhou Unicorn Innovation Enterprises was announced, featuring a biopharmaceutical company specializing in mRNA-encoded TCR-T cell therapy.Laien BioSuccessfully selected into the "Future Unicorn" innovative enterprise list. This honor not only affirms the innovation capability and development potential of Guangzhou Laien Biological Medicine Co., Ltd., but also highlights Guangzhou's outstanding achievements in nurturing emerging innovative enterprises.

The discovery of Guangzhou Unicorn Innovation Enterprises, guided by the Guangzhou Science and Technology Bureau and collected by the Guangzhou Association of Science and Technology Innovation Enterprises, was jointly released by multiple departments. It aims to uncover and cultivate companies like Guangzhou Laien Biological Medicine Co., Ltd., which have been established for less than ten years but demonstrate strong innovation capabilities and rapid growth.Guangzhou Laien Biological Medicine Co., Ltd. has met the criteria for a "Future Unicorn" company with its technological breakthroughs and market potential in the biopharmaceutical field, having received institutional equity investment and possessing a market valuation between 100 million (inclusive) and 1 billion US dollars.

After being selected for the list, Guangzhou Laien Biological Medicine Co., Ltd. will enjoy a series of empowerment services. These include capital matchmaking, with opportunities to engage in in-depth cooperation with financial institutions such as banks, funds, investment firms, and securities companies, broadening financing channels. In terms of IPO cultivation, the company will collaborate with the SSE Southern Center for guidance, increasing its exposure in the capital market. Industrial matchmaking will facilitate partnerships with key and leading enterprises in Guangzhou, expanding business scope. The unicorn cultivation system provides one-stop scientific and technological innovation services and opportunities for industry-academia-research collaboration. Policy support ensures timely access to policy benefits, while brand promotion leverages mainstream media to enhance corporate visibility and influence.

Laien Bio, a clinical-stage biotech company incubated by Singapore's Agency for Science, Technology and Research (A*STAR),LeadGlobal mRNA-encoded TCR-T cell therapy for the treatment of solid tumors and infectious diseases. The leading product focuses on liver cancer treatment and is the world's first FDA-approved.International Multicenter Phase 1b/2 Clinical Trial, UtilizingTCR-T Cell Therapy Targeting HBV for the Treatment of Liver Cancer Granted FDA Fast Track and Orphan Drug Designation. In November 2024, Guangzhou Laien Biological Medicine Co., Ltd. received implied IND approval from the Chinese regulatory authority, marking a significant breakthrough for the company in the field of TCR-T cell therapy.

Leveraging its mRNA technology and AI-powered TCR neoantigen discovery platform, Guangzhou Laien Biological Medicine Co., Ltd. is actively expanding into various solid tumors, including lung cancer, breast cancer, and gastrointestinal tumors. The company is also developing autologous cell therapies and off-the-shelf therapy products, utilizing mRNA-LNP delivery technology to create in vivo TCR-T therapies, significantly reducing costs.In terms of financing cooperation, Guangzhou Laien Biological Medicine Co., Ltd. has completed over 300 million yuan in financing, led by Guangzhou Industrial Investment Group, with participation from Guojù Venture Capital, a directly affiliated enterprise of Guangzhou High-Tech Zone Group, and Nade Fund of Shijiang Group. Currently, Laien Biological has established its China headquarters in Guangzhou's Sino-Singapore Knowledge City, working in tandem with Singapore's GMP innovative drug base to create an integrated innovative drug hub for research, clinical operations, and production. It has become a benchmark company in the field of cell therapy under Sino-Singapore cooperation.

Looking ahead, Guangzhou Laien Biological Medicine Co., Ltd. will leverage the "Future Unicorn" empowerment services to broaden financing channels, deepen industry-university-research cooperation, accelerate the entry of its R&D pipeline into the clinical stage, and advance the layout of off-the-shelf therapies, providing global patients with safer, more effective, and lower-cost breakthrough treatment solutions.

Highlights:

World's First! Laien Bio's mRNA-Encoded TCR-T Approved for Clinical Trials, Precisely Targeting Hepatocellular Carcinoma

Guangzhou Laien Biological Medicine Co., Ltd. Honored as "2024 Hurun China New Medical Powerhouse Enterprise"

Reprint: Academician Wang Fusheng: Progress in Clinical Research on Immune Therapy for Chronic Hepatitis B

LIONTCR

WeChat ID |Laien Bio

Official Website｜https://www.liontcr.com/